Cannabis Law Report

FEBRUARY 16, 2022

A 28-page DEA report — authored in August of 2021, and based on Department of Health and Human Services reviews of these psychedelics from 2012 — states, “These five tryptamines have no known medical use in the United States and are not marketed internationally as approved drug products. Read full report at.

DEA 52

DEA Safety Treatment Law 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

SEPTEMBER 2, 2021

Court of Appeals for the Ninth Circuit dismissed a petition brought by a team of cannabis researchers, scientists, and military veterans to require that the Drug Enforcement Administration (DEA) reevaluate marijuana’s status as a Schedule I substance under the Controlled Substances Act (CSA). Source: [link].

DEA 102

DEA Marijuana Treatment Legalization 102

Freedom Leaf

OCTOBER 15, 2018

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

JULY 7, 2021

Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. The INCBA supports lawyers in their practice of law as they serve all aspects of the cannabis and related industries. Hemp Industries Association v.

DEA 111

DEA Hemp Cultivation Advocacy 111

Canna Law Blog

JUNE 13, 2023

Drug Enforcement Administration (DEA) to implement and enforce the relevant provisions of the Controlled Substances Import and Export Act which makes it a crime to bring controlled substances into the country without a proper license. CBP coordinates with a wide range of partner government agencies (e.g., FDA, EPA, DOT, ATF, CPSC, etc.)

DEA 64

DEA Marijuana Hemp Concentrates 64

United Patients Group

APRIL 3, 2023

Introduction A cannabis ‘prescription’ is written by a doctor to be dispensed at a pharmacy (i.e. A recommendation from a physician is simply permission (‘recommendation’) for the patient to use cannabis, which can be obtained in any state where medical marijuana is legal.

DEA 52

DEA Patients Conditions Cannabis 52

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Veriheal

DECEMBER 28, 2021

Over the last few decades, the cannabis plant and its many components have been the focal point of research and stiff debate. D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted.

Research and Development 98

Research and Development Chronic Pain Treatment Medicine 98

Veriheal

AUGUST 23, 2023

A disputable new social media drug reporting bill believes that social media companies should screen client posts and report any drug-related exercises to the DEA. The post A Proposed Social Media Drug Reporting Bill Raises Privacy Concerns appeared first on Cannabis Central.

Media 52

Media DEA Advocacy Legislation 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. Defining Psychedelics.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

FloridaMarijuana.net

JULY 8, 2018

5 cannabis strains to treat PTSD? Cannabis offers significant therapeutic benefits for a wide range of medical conditions. The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs). 5 cannabis strains to treat PTSD: 1. Medical marijuana can contribute to a patient’s overall health.

Strains 190

Strains Indica Hybrid Research and Development 190

SpeedWeed

JULY 23, 2021

This is the first time a research license for this type of work has been granted outside of state and city research licenses to study cannabis. . Thanks to the new DEA research license, MedPharm will now be able to supply investigational medications across state lines for the purpose of clinical trials.

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Veriheal

APRIL 11, 2022

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Drug Enforcement Agency (DEA).

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Veriheal

NOVEMBER 11, 2023

Many states in the US have legalized cannabis, thirty-eight states to be exact. Despite the widespread adoption, the Food and Drug Administration still classifies cannabis as a Schedule One drug. Simply put, in the eyes of federal law, cannabis is illegal. Is Medical Cannabis Legal? allow the use of medical cannabis.

Law 62

Law Chronic Pain Conditions Legislation 62

Cannabis Law Report

NOVEMBER 20, 2021

he Alabama State Board of Medical Examiners Thursday announced draft rules to govern how physicians can recommend medical cannabis to eligible patients. The draft rules were developed in accordance with the state’s new law on medical cannabis, which was approved earlier this year by the state Legislature and signed into law by the governor.

Patients 52

Patients DEA Dispensary Conditions 52

CannaMD

AUGUST 8, 2020

– because today’s post is a deep dive into everything you need to know about the most popular cannabis compound around. Let’s clear up one of the biggest sources of confusion right off the bat: CBD is a cannabis compound called cannabidiol. Researchers believe cannabis contains over 100 unique chemical compounds!

CBD 100

CBD DEA Research and Development Hemp 100

The Fresh Toast

APRIL 17, 2023

5 Facts About Glaucoma And Medical Marijuana Medical marijuana glaucoma treatment can help reduced eye pressure and relieve pain. Here's what you need to know about using cannabis for eye health. The post 5 Facts About Glaucoma And Medical Marijuana appeared first on The Fresh Toast.

Marijuana 98

Marijuana Treatment DEA Topical 98

Cannabis Law Report

MARCH 2, 2020

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression. In 2018, the U.S.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

TheAnswerPage

APRIL 14, 2020

Epidiolex, a CBD product derived from the cannabis plant, received FDA approval for the treatment of Lenox Gastaut syndrome and Dravet syndrome in November 2018. Since Epidiolex is no longer a controlled substance, physicians are not required to notify the DEA when prescribing the medication. Is Epidiolex a controlled substance?

DEA 52

DEA Treatment Programs Medicine 52

SpeedWeed

AUGUST 11, 2021

MAPS, The Multidisciplinary Association for Psychedelic Substances, was awarded a $12,979,050 million grant from the state of Michigan to fund a study on PTSD and cannabis on August 10. This grant enables more rigorous study, overseen by the FDA, which may lead to cannabis flower becoming prescribable medicine someday.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

AUGUST 18, 2022

Smith , a partner with the firm and co-leader of the firm’s Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments. Tweet this. However, change appears imminent. ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

AUGUST 5, 2019

This week I moderated a webinar at the Food & Drug Law Institute (FDLI) on the regulation of cannabis-derived products. In the federal executive branch alone, DOJ (especially DEA), USDA, FDA, and NIH all play major roles. In the federal executive branch alone, DOJ (especially DEA), USDA, FDA, and NIH all play major roles.

DEA 55

DEA Food Treatment CBD 55

MedicalJane

JUNE 29, 2018

None of the approved drugs contain, or are derived from, the whole cannabis plant. The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. a Canada-based medical cannabis firm.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

CannaMD

NOVEMBER 20, 2020

Making matters worse, there’s only one farm in the entire country with DEA approval to cultivate marijuana for research purposes. Given medical marijuana’s proven ability to alleviate pain, how much longer will it be before employers start allowing medical cannabis use? Cannabis vs. Opioids. More Cannabis. Get Started.

Therapy 80

Therapy Treatment DEA CBD 80

Cannabis Law Report

OCTOBER 4, 2021

Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment. This is a policy where the federal government, the DEA, will refrain from taking prosecutorial action if state law permits, regulates, and carefully controls the use of a drug.

Therapy 52

Therapy Patients Law Clinical Trials 52

Veriheal

MAY 6, 2022

The good news is that cannabis could be the tool for a good night’s sleep. Since cannabis may suppress REM sleep, many regular consumers don’t remember their dreams after using the plant. Conflicting Evidence on Cannabis and Sleep. THC’s Connection to REM Sleep.

Sleep 98

Sleep Cannabinoids THC CBD 98

SpeedWeed

AUGUST 8, 2021

It’s the first cannabis-derived pharmaceutical to be legalized in many countries around the world, including the UK, Spain, United States, Canada, and New Zealand. . “It’s not just street cannabis put into a bottle,” GW Pharmaceutical CEO Justin Gover once told the Guardian. “We And the weed was (and still is) terrible !

Cannabinoids 64

Cannabinoids Pharmaceutical DEA Medicine 64

Cannabis Law Report

JANUARY 28, 2022

She now is a medical marijuana practitioner who knows what cannabis can do. She now has written a book that focuses on dispelling those marijuana myths conjured up by cannabis opponents over the years. The book, “The Brain on Cannabis: What You Should Know About Recreational and Medical Marijuana,” came out in late 2021.

Marijuana 52

Marijuana DEA Treatment Sleep 52

Cannabis Law Report

OCTOBER 5, 2021

“This shows that combination of psilocybin and music has a strong emotional effect, and we believe that this will be important for the therapeutic application of psychedelics if they are approved for clinical use,” said lead researcher Dea Siggaard Stenbæk , Associate Professor University of Copenhagen.

Clinical Trials 52

Clinical Trials Research and Development DEA Therapy 52

Cannabis Law Report

JUNE 11, 2021

In turn, here are the top 6 questions we’ve been getting lately around ketamine clinics: Isn’t the regulation of ketamine clinics just like adult-use/medicinal cannabis businesses? Pursuant to the federal Controlled Substances Act, cannabis is an illegal schedule I controlled substance while ketamine is on schedule III. No, it’s not.

Law 104

Law Compliance Compliance DEA 104

Burns Levinson (Cannabusiness advisory)

OCTOBER 3, 2018

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval.

CBD 40

CBD DEA Epilepsy Pharmaceutical 40

Cannabis Law Report

AUGUST 12, 2022

Drug policy topics have become a consistent feature of the Austin-based event in recent years as more states have legalized cannabis and moved to reform laws around psychedelics like psilocybin locally and at the state level. Under the cannabis category, there are 61 options. Is cannabis actually. Green or not?

Research and Development 52

Research and Development Events Topical Policy 52

Veriheal

AUGUST 24, 2022

This campaign was backed by New Approach PAC, a nationwide political organization that is focused on supporting progressive reform surrounding cannabis and criminal justice policies. In May 2022, Connecticut’s governor signed a budget bill that included a provision for the implementation of psychedelic-assisted therapy treatment centers.

Legalization 109

Legalization Medicine Decriminalization Research and Development 109

Cannabis Law Report

JULY 9, 2021

Not only are more and more jurisdictions decriminalizing the use of psychedelics for recreational purposes, but it appears that psychedelic substances are the new horizon for the treatment of severe psychological disorders and other ailments. Drug Enforcement Agency (“DEA”). Id ; 21 CFR 312.1-10; 10; 312.80-88; 88; 312.300 et seq.

Law 105

Law Therapy Clinical Trials Research and Development 105

Medicinal Genomics

JULY 13, 2023

one of just seven federally DEA- licensed cannabinoid research labs, had some encouraging news about how cannabinoids and cannaflavins can lengthen life spans while improving health spans. Punja sounded the alarm on the Hop Latent Viroid plague decimating the crops of western grower, calling it the “Covid of Cannabis.”

Research and Development 52

Research and Development Cannabinoids Medicine DEA 52